Applied Therapeutics, Inc. — Director's Dealing 2021

Feb 26, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Applied Therapeutics Inc. (APLT)
CIK: 0001697532
Period of Report: 2021-02-23

Reporting Person: Perfetti Riccardo (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-23	Common Stock	M	465	$1.44	Acquired	465	Direct
2021-02-23	Common Stock	S	465	$21.84	Disposed	0	Direct
2021-02-24	Common Stock	M	2125	$1.44	Acquired	2125	Direct
2021-02-24	Common Stock	S	1525	$23.71	Disposed	600	Direct
2021-02-24	Common Stock	S	600	$24.57	Disposed	0	Direct
2021-02-25	Common Stock	M	1295	$1.44	Acquired	1295	Direct
2021-02-25	Common Stock	S	1295	$23.20	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-23	Stock Option (Right to Buy)	$1.44	M	465	Disposed	2028-12-16	Common Stock (465)	Direct
2021-02-24	Stock Option (Right to Buy)	$1.44	M	2125	Disposed	2028-12-16	Common Stock (2125)	Direct
2021-02-25	Stock Option (Right to Buy)	$1.44	M	1295	Disposed	2028-12-16	Common Stock (1295)	Direct

Footnotes

F1: Compensatory options granted under Applied Therapeutics, Inc.'s 2016 Equity Incentive Plan, exercised automatically pursuant to the reporting person's written trading plan previously entered into on September 16, 2020, providing for the sale of shares underlying compensatory options in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2: Automatic sales made pursuant to the reporting person's pre-existing written trading plan, providing for the sale of shares underlying compensatory options in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F3: Weighted average price. These shares were sold in multiple transactions at prices ranging from $21.6200 to $22.1350 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F4: Weighted average price. These shares were sold in multiple transactions at prices ranging from $23.2300 to $24.1500 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F5: Weighted average price. These shares were sold in multiple transactions at prices ranging from $24.5100 to $24.6500 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F6: Weighted average price. These shares were sold in multiple transactions at prices ranging from $22.7100 to $23.6300 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F7: Thirty-three percent (33%) of the shares subject to the option vested on August 27, 2018, and one twenty-fourth (1/24th) of the remaining shares subject to the Option vested or shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date.